GeneDx Holdings Corp. (WGS)

72.43 3.78 (5.51%)

As of 2026-10-15 14:05:47 EST

GeneDx is an American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing (WGS) and whole exome sequencing (WES) for the diagnosis of rare and inherited disorders. The company provides genetic testing services to healthcare providers, hospitals, and health systems, and contributes to advancements in genomic medicine through research, biopharma partnerships, and advocacy. The company is headquartered in Stamford, Connecticut, with its clinical laboratory in Gaithersburg, Maryland, and is publicly traded on the Nasdaq under the ticker symbol WGS.

Traded asNasdaq: WGS
ISINUS81663L2007
CIK0001818331
LEI—
EIN851966622
SectorBiotechnology
IndustryServices-Health Services
CEOKatherine Stueland
Employees—
Fiscal Year End1231
Address333 LUDLOW STREET, STAMFORD, CT, 06902
Phone888-729-1206
Websitehttps://www.genedx.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
WGSGeneDx Holdings Corp.2026-10-15 14:05:4772.433.785.51
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
WGS0001818331GeneDx Holdings Corp.US81663L2007—851966622Nasdaq8000Services-Health Services1231DE333 LUDLOW STREETSTAMFORDCT06902UNITED STATESUS888-729-1206333 LUDLOW STREET, STAMFORD, CT, 06902333 LUDLOW STREET, STAMFORD, CT, 06902Sema4 Holdings Corp.Biotechnology2000Katherine Stueland—https://www.genedx.com/1,660,000,00029,803,16429,822,541GeneDx is an American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing (WGS) and whole exome sequencing (WES) for the diagnosis of rare and inherited disorders. The company provides genetic testing services to healthcare providers, hospitals, and health systems, and contributes to advancements in genomic medicine through research, biopharma partnerships, and advocacy. The company is headquartered in Stamford, Connecticut, with its clinical laboratory in Gaithersburg, Maryland, and is publicly traded on the Nasdaq under the ticker symbol WGS.2026-10-09 02:19:29
This is a preview of the latest data. Subscribe to access the full data.
WGS Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
WGS Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20251,660,000,0001,228,000,000284.259329,288,7391,220,4654.3482
2024432,000,000336,000,00035028,068,2742,014,7237.733
202396,000,000-122,000,000-55.963326,053,551-772,193,735-96.7362
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Kevin FeeleyChief Financial Officer, Chief Operating Officer2025500,60003,756,926414,15017,2504,688,926
Katherine StuelandChief Executive Officer2025715,869011,738,6001,075,50017,25013,547,219
Katherine StuelandChief Executive Officer2024675,000950,0002,796,800004,421,800
Kevin FeeleyChief Financial Officer, Chief Operating Officer2024450,000315,000568,100016,5001,349,600
Jason RyanChair20246,4900338,480—96,500441,470
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20211,200
20203
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue427,539,000305,450,000202,566,000
Cost Of Revenue129,366,000111,053,000112,560,000
Gross Profit298,173,000194,397,00090,006,000
Research And Development Expenses72,026,00045,722,00058,266,000
General And Administrative Expenses150,819,000101,110,000133,755,000
Operating Expenses311,250,000217,610,000270,602,000
Operating Income-13,077,000-23,213,000-180,596,000
Net Income-21,021,000-52,286,000-175,767,000
Earnings Per Share Basic-0.73-1.94-7.23
Earnings Per Share Diluted-0.73-1.94-7.23
Weighted Average Shares Outstanding Basic28,641,73426,891,21324,311,989
Weighted Average Shares Outstanding Diluted28,641,73426,891,21324,311,989
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents104,997,00085,212,00099,681,000
Marketable Securities Current66,285,00055,973,00030,467,000
Accounts Receivable74,370,000——
Inventories13,951,00010,650,0008,777,000
Non Trade Receivables———
Other Assets Current1,511,0001,079,00010,598,000
Total Assets Current268,288,000197,968,000182,339,000
Marketable Securities Non Current———
Property Plant And Equipment45,693,00032,893,00032,479,000
Other Assets Non Current4,316,0004,306,0004,413,000
Total Assets Non Current255,422,000221,412,000236,417,000
Total Assets523,710,000419,380,000418,756,000
Accounts Payable2,461,0007,954,00010,238,000
Deferred Revenue———
Short Term Debt4,542,0001,211,000497,000
Other Liabilities Current46,859,00011,504,00012,154,000
Total Liabilities Current108,908,00054,817,00058,818,000
Long Term Debt54,542,00055,753,00056,250,000
Other Liabilities Non Current1,641,0005,519,00014,735,000
Total Liabilities Non Current106,620,000119,316,000131,921,000
Total Liabilities215,528,000174,133,000190,739,000
Common Stock3,0002,0002,000
Retained Earnings-1,373,495,000-1,352,474,000-1,300,188,000
Accumulated Other Comprehensive Income936,000830,000425,000
Total Shareholders Equity308,182,000245,247,000228,017,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization9,600,0007,900,00019,700,000
Share Based Compensation Expense32,162,0009,138,000-326,000
Other Non Cash Income Expense——1,700,000
Change In Accounts Receivable36,231,0005,421,000-10,263,000
Change In Inventories3,436,0002,585,000-975,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable12,100,000-20,461,000-46,953,000
Change In Other Liabilities-11,970,000-3,722,0002,526,000
Cash From Operating Activities33,279,000-28,496,000-180,147,000
Purchases Of Marketable Securities55,676,00066,302,00047,670,000
Sales Of Marketable Securities2,062,000601,00017,765,000
Acquisition Of Property Plant And Equipment19,017,0005,491,0005,250,000
Acquisition Of Business—012,144,000
Other Investing Activities———
Cash From Investing Activities-61,517,000-30,132,000-43,726,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock46,704,00046,496,000285,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt0048,549,000
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities48,025,00044,162,000186,238,000
Change In Cash19,787,000-14,466,000-37,635,000
Cash At End Of Period104,997,00085,212,00099,681,000
Income Taxes Paid1,275,0001,167,0001,465,000
Interest Paid6,413,0006,677,0003,041,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-0.73-1.94-7.23
Price To Earnings Ratio-178.1644-39.6186-0.3804
Earnings Growth Rate-62.3711-73.1674343.5583
Price Earnings To Growth Ratio2.85650.5415-0.0011
Book Value Per Share10.75999.129.3788
Price To Book Ratio12.08758.42770.2932
Ebitda-10,146,000-43,219,000-153,488,000
Enterprise Value3,679,230,924.042,038,610,631.1823,923,969.75
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.19170.23230.2489
Capital Expenditures22,400,0008,314,000652,000
Free Cash Flow10,879,000-36,810,000-180,799,000
Return On Equity-0.0682-0.2132-0.7709
One Year Beta1.63541.3045-12.6391
Three Year Beta-1.8641-0.4073-0.4309
Five Year Beta0.2673-0.2587-0.5003
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Fuchs ThomasDirector2026-09-171,146A1,146
Fuchs ThomasDirector2026-09-171,146D2,292
Feeley KevinCHIEF FINANCIAL OFFICER2026-09-167,197A48,673
Feeley KevinCHIEF FINANCIAL OFFICER2026-09-16586D48,087
Feeley KevinCHIEF FINANCIAL OFFICER2026-09-1652D48,035
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
State of Alaska, Department of Revenue2026-09-30113,0001,56472.2506
WOLFF WIESE MAGANA LLC2026-09-308,82112272.3033
Assenagon Asset Management S.A.2026-09-3045,723,460632,41372.3
Cedar Mountain Advisors, LLC2026-09-30506772.2857
Fortitude Family Office, LLC2026-09-301,0851572.3333
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2026-08-31Class IRKSIX17,1611,455,424.411.3892
TRUST FOR PROFESSIONAL MANAGERS2026-08-31Class ARKSAX17,1611,455,424.411.3892
CALAMOS INVESTMENT TRUST/IL2026-07-31Class ACTASX56,7593,695,578.490.4823
CALAMOS INVESTMENT TRUST/IL2026-07-31Class R6CTSOX56,7593,695,578.490.4823
CALAMOS INVESTMENT TRUST/IL2026-07-31Class ICTSIX56,7593,695,578.490.4823
This is a preview of the latest data. Subscribe to access the full data.